



Camille L. Fletcher

Associate
cfletcher@pbwt.com
Tel: 212-336-2379
Fax: 212-336-7921

Camille Fletcher is an Associate in the Firm's Litigation department. From 2016 to 2017, Ms. Fletcher served as a law clerk to the Hon. Kiyo A. Matsumoto and the Hon. Pamela K. Chen of the United States District Court for the Eastern District of New York.

Education

- Stanford Law School (J.D., 2013)
 - Editor-in-Chief, *Stanford Journal of Civil Rights and Civil Liberties*
- Baruch College, Zicklin School of Business, CUNY (B.B.A., *cum laude*, 2007)

Admissions

- U.S. District Court, Southern District of New York
- New York

Misbranded Blog

Misbranded is Patterson Belknap's blog covering false advertising litigation—both consumer class actions and competitor suits—with a particular focus on FDA-regulated products (foods/beverages, pharmaceuticals, cosmetics, and dietary supplements). Writing from the industry perspective, we provide timely updates on important cases, surveys of litigation trends, and in-depth analyses of “hot” legal issues. Our firm pioneered the modern practice of false advertising law more than 40 years ago, bringing the first competitor suits under the Lanham Act. In the decades since, we have continued to practice at the cutting edge, handling many of the field's most groundbreaking cases on behalf of the nation's best-known businesses. Today, led by [Steven A. Zalesin](#), our team advocates creatively, strategically, and efficiently on behalf of our clients at all phases of litigation, from pre-complaint demands to Supreme Court appeals.

Liability Immunity Under The PREP Act: A Potent New Defense Against COVID-Related False Advertising Claims

May 21, 2020

Our national response to the COVID-19 pandemic has been made more difficult by a shortage of personal protective equipment and lifesaving drugs and medical devices. Some evidence suggests that manufacturers' fear of lawsuits has exacerbated these shortages. Seeking to allay...

And So It Begins: The Wave of CBD-Related Consumer Actions Has Arrived

January 31, 2020

It was only a matter of time. As we anticipated last summer, the plaintiffs' bar recently filed a slew of false advertising suits against manufacturers of products infused or made with cannabidiol, a/k/a CBD. This development was a fait accompli,...

CBD: The Next Cure-All—and the Next Frontier for False Advertising Litigation?

August 6, 2019

Cannabidiol—better known as “CBD,” a cannabis-derived compound—is one of the latest crazes in the consumer packaged goods industry. CBD sales are expected to top \$5 billion in 2019—a 700% increase from 2018—and reach \$24 billion in sales by 2023.[1] Manufacturers...

How Much Is Too Much Deference to FDA Warning Letters in Consumer Class Actions?

June 3, 2019

Consumer class actions involving goods regulated by the Food and Drug Administration (“FDA”) coexist in parallel with FDA enforcement efforts. Consumers have no private right of action to enforce the Food, Drug, and Cosmetics Act (“FDCA”)—the statute the FDA is...